Hims & Hers Health (NYSE:HIMS) Stock Price Expected to Rise, Deutsche Bank Aktiengesellschaft Analyst Says

Hims & Hers Health (NYSE:HIMS) had its price target boosted by equities research analysts at Deutsche Bank Aktiengesellschaft from $23.00 to $27.00 in a report issued on Wednesday, Benzinga reports. The brokerage presently has a “hold” rating on the stock. Deutsche Bank Aktiengesellschaft’s price objective indicates a potential upside of 15.38% from the stock’s previous close.

Several other equities research analysts have also commented on HIMS. Piper Sandler reissued a “neutral” rating and set a $21.00 price target (up previously from $18.00) on shares of Hims & Hers Health in a research note on Tuesday. TD Cowen boosted their target price on Hims & Hers Health from $15.00 to $25.00 and gave the stock a “buy” rating in a research report on Thursday, July 11th. Bank of America raised their price target on Hims & Hers Health from $23.00 to $25.00 and gave the company a “buy” rating in a research report on Monday, October 21st. Imperial Capital downgraded shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a report on Friday, August 9th. Finally, Truist Financial lifted their target price on shares of Hims & Hers Health from $13.00 to $23.00 and gave the stock a “hold” rating in a research report on Thursday, July 18th. Eight equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $21.00.

Hims & Hers Health Stock Up 13.4 %

HIMS stock traded up $2.76 on Wednesday, reaching $23.40. 19,978,396 shares of the company’s stock were exchanged, compared to its average volume of 8,532,059. The stock has a fifty day moving average of $18.10 and a 200-day moving average of $18.19. The firm has a market cap of $5.03 billion, a PE ratio of 300.91 and a beta of 1.06. Hims & Hers Health has a twelve month low of $6.58 and a twelve month high of $25.74.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.26. Hims & Hers Health had a net margin of 1.70% and a return on equity of 5.25%. The business had revenue of $401.56 million for the quarter, compared to analysts’ expectations of $382.20 million. During the same period in the prior year, the company posted ($0.04) EPS. The business’s revenue for the quarter was up 77.1% on a year-over-year basis. On average, equities research analysts predict that Hims & Hers Health will post 0.22 EPS for the current fiscal year.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, insider Soleil Boughton sold 2,339 shares of the firm’s stock in a transaction dated Tuesday, October 29th. The stock was sold at an average price of $23.16, for a total value of $54,171.24. Following the sale, the insider now directly owns 169,935 shares of the company’s stock, valued at approximately $3,935,694.60. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Hims & Hers Health news, CEO Andrew Dudum sold 188,888 shares of the firm’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $14.56, for a total value of $2,750,209.28. Following the transaction, the chief executive officer now directly owns 33,502 shares of the company’s stock, valued at $487,789.12. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Soleil Boughton sold 2,339 shares of the company’s stock in a transaction dated Tuesday, October 29th. The stock was sold at an average price of $23.16, for a total value of $54,171.24. Following the completion of the sale, the insider now directly owns 169,935 shares of the company’s stock, valued at $3,935,694.60. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 650,659 shares of company stock worth $11,712,198. 17.71% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Victory Capital Management Inc. grew its holdings in Hims & Hers Health by 164.9% during the 3rd quarter. Victory Capital Management Inc. now owns 51,577 shares of the company’s stock valued at $950,000 after purchasing an additional 32,108 shares in the last quarter. WealthPlan Investment Management LLC purchased a new stake in shares of Hims & Hers Health during the third quarter worth about $1,042,000. Versor Investments LP acquired a new position in shares of Hims & Hers Health in the third quarter worth about $634,000. Los Angeles Capital Management LLC boosted its holdings in Hims & Hers Health by 40.8% in the third quarter. Los Angeles Capital Management LLC now owns 40,353 shares of the company’s stock valued at $743,000 after purchasing an additional 11,686 shares during the last quarter. Finally, State of New Jersey Common Pension Fund D grew its stake in Hims & Hers Health by 30.1% during the 3rd quarter. State of New Jersey Common Pension Fund D now owns 123,587 shares of the company’s stock valued at $2,276,000 after purchasing an additional 28,600 shares in the last quarter. 63.52% of the stock is owned by institutional investors and hedge funds.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.